Skip to main content
Clinical Trials/NCT04868409
NCT04868409
Completed
Phase 4

A Single Blinded Multicenter Randomized Study Comparing Intubating Conditions During Rapid Sequence Induction With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg in Elderly Patients (≥ 80 Years Old)

Matias Vested4 sites in 1 country102 target enrollmentAugust 12, 2021

Overview

Phase
Phase 4
Intervention
Rocuronium
Conditions
Intubation Conditions
Sponsor
Matias Vested
Enrollment
102
Locations
4
Primary Endpoint
Intubation conditions
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to determine the proportion of excellent tracheal intubation conditions at 60 seconds after administration of either rocuronium 1.0 mg/kg or suxamethonium 1 mg/kg in patients with age ≥ 80 years during rapid sequence induction.

Detailed Description

Elderly patients are frail and susceptible to complications in the perioperative period. They are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. These physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia as for example neuromuscular blocking agents (NMBA). The number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia with employment of rapid sequence induction (RSI) within the next decades. RSI and intubation is performed when there is an increased risk of pulmonary aspiration of gastric contents. Because of its fast onset time succinylcholine is often used to facilitate tracheal intubation during RSI. However, succinylcholine has certain side effects such as cardiac arrhythmia, hyperkalemia, muscle soreness, short duration of action and shorter time to desaturation. It is therefore unknown if succinylcholine 1.0 mg/kg provides better intubating conditions compared to high dose rocuronium (1.0 mg/kg) in the elderly. In this matter, there remains a need for a study to investigate the optimal muscle relaxant during rapid sequence induction for facilitating tracheal intubation in the elderly.

Registry
clinicaltrials.gov
Start Date
August 12, 2021
End Date
March 17, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Matias Vested
Responsible Party
Sponsor Investigator
Principal Investigator

Matias Vested

MD PhD

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Scheduled for surgery under general anesthesia with indication for rapid sequence induction
  • American Society of Anesthesiologists physical status classification (ASA) I to IV
  • Informed consent (see appendix 1)
  • Body mass index (BMI) \< 35 kg/m2
  • Read and understand Danish

Exclusion Criteria

  • Neuromuscular disease
  • Known allergy to rocuronium and/or suxamethonium
  • Known hyperkalemia \> 5 mM
  • Previous malignant hyperthermia
  • Known homozygote plasmacholinesterase gene mutation variant a or s
  • Known impaired kidney function defined as estimated glomerular filtration rate (eGFR) \< 30

Arms & Interventions

Rocuronium group

Rocuronium 1 mg/kg

Intervention: Rocuronium

Suxamethonium group

Suxamethonium 1 mg/kg

Intervention: Suxamethonium

Outcomes

Primary Outcomes

Intubation conditions

Time Frame: 60 seconds after induction of anaesthesia

Tracheal intubating conditions according to the Fuchs-Buder scale: Excellent, good or poor depending on laryngoscopy, vocal chords and reaction to intubation,

Secondary Outcomes

  • Time to TOF count 0(within 15 minutes)
  • Desaturation(within 15 minutes)
  • Time to tracheal intubation(within 15 minutes after administration of muscle relaxant)
  • cardiac arrythmia(within 15 minutes of anesthesia)
  • First pas succes rate(within 15 minutes)
  • Intubation conditions(within 15 minutes)
  • sore throat(24 hours after anaesthesia)
  • muscle soreness(24 hours after anaesthesia)

Study Sites (4)

Loading locations...

Similar Trials